This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.78% and 6.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Bears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -10% and 7.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.50% and 5.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Bionano (BNGO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Bionano (BNGO) stock based on the movements in the options market lately.